A judicial investigation is underway in Belgium following the death of a 46-year-old man, raising concerns about the increasing prevalence of illicitly obtained Ozempic. The case, reported February 23rd, highlights the potential dangers associated with seeking prescription medications through unregulated channels, a growing problem fueled by the drug’s popularity for off-label weight loss. Authorities are examining whether the man’s death resulted from a counterfeit or improperly sourced version of semaglutide, the active ingredient in Ozempic, as reports of adverse effects and potential long-term health risks linked to the drug surface [[3]].
Investigation Opened After Man’s Death Potentially Linked to Illicit Ozempic
A judicial investigation has been launched in Belgium following the death of a 46-year-old man from Lommel, with preliminary findings suggesting a possible overdose of illegally obtained Ozempic.
Authorities opened the inquiry after the man’s death on February 23, according to reports. The investigation centers on whether the man’s death was connected to the use of counterfeit or improperly sourced semaglutide, the active ingredient in Ozempic, a medication typically prescribed for type 2 diabetes.
The drug has gained widespread attention recently due to its off-label use for weight loss, leading to shortages of the legitimate medication and a rise in the availability of fake or adulterated versions. The case underscores the dangers associated with obtaining prescription drugs through unofficial channels.
Details surrounding the man’s death remain limited as the investigation continues. Authorities have not released further information regarding the source of the suspected illicit Ozempic or the circumstances leading to the overdose.
The investigation is ongoing, and further updates will be provided as they become available.
